Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep;119(9):7827-7833.
doi: 10.1002/jcb.27183. Epub 2018 Jun 22.

Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma

Tasuku Kiyuna  1   2   3 , Yasunori Tome  3 , Takashi Murakami  1   2 , Ming Zhao  1 , Kentaro Miyake  1   2 , Kentaro Igarashi  1   2 , Kei Kawaguchi  1   2 , Masuyo Miyake  1   2 , Hiromichi Oshiro  1   2 , Takashi Higuchi  1   2 , Yunfeng Li  4 , Sarah M Dry  4 , Scott D Nelson  4 , Tara A Russell  5 , Mark A Eckardt  6 , Arun S Singh  7 , Fuminori Kanaya  3 , Fritz C Eilber  5 , Robert M Hoffman  1   2
Affiliations

Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma

Tasuku Kiyuna et al. J Cell Biochem. 2018 Sep.

Abstract

Pleomorphic liposarcoma (PLPS) is a recalcitrant soft-tissue sarcoma (STS) subtype in need of transformative therapy. We have previously established a patient-derived orthotopic xenograft (PDOX) model, of PLPS with PDGFRA amplification, using surgical orthotopic implantation. In the current study, the PLPS PDOX model was randomized into 3 groups of 7 mice each: untreated control; doxorubicin (DOX)-treated; and treated with Salmonella typhimurium A1-R (S. typhimurium A1-R) expressing green fluorescent protein (GFP). Tumor volume and body weight were monitored during the treatment period. The PLPS PDOX was resistant to DOX. In contrast, the PLPS PDOX was highly sensitive to S. typhimurium A1-R. There was no significant body-weight loss among these 3 groups. Fluorescence imaging demonstrated that S. typhimurium A1-R-GFP was very effective to target the PLPS PDOX tumor. The current study demonstrates that a PLPS PDOX, resistant to first-line therapy DOX, was highly sensitive to tumor targeting S. typhimurium A1-R.

Keywords: PDGFRA amplification; Salmonella typhimurium A1-R; green fluorescent protein; patient-derived orthotopic xenograft; pleomorphic liposarcoma; soft-tissue sarcoma; tumor targeting.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Treatment protocol of pleomorphic liposarcoma (PLPS) PDOX
Treatment protocol. Group 1, untreated control (n =7); Group 2, treated with doxorubicin (DOX) (3 mg/kg, i.v., weekly, 2 weeks, n = 7); Group 3, treated with S. typhimurium A1-R (5×107CFU/100 ml, i.v., weekly, 2 weeks, n = 7). All mice included in this study were sacrificed on day 15 to harvest tumor for further histological evaluation.
Figure 2
Figure 2. Efficacy of S. typhimurium A1-R vs. DOX on the PLPS PDOX
The line graphs show relative tumor volume on each time point. Relative tumor is the tumor volume at any given time point at the beginning of the treated period divided by the tumor volume. Error bars: ± SD. * p < 0.05.
Figure 3
Figure 3. Macroscopic imaging of control and treated tumor
Images were obtained at the end of the treatment period. Scale bar: 10mm.
Figure 4
Figure 4. Tumor targeting S. typhimurium A1-R-GFP of the PLPS PDOX
S. typhimurium, expressing green fluorescent protein (GFP), was cultivated in serial dilution from supernatants of tumor homogenates by mincing tumor tissue on agar medium. Grown colonies of bacterial were imaged by GFP fluorescence. Fluorescent bacteria were detected at all dilutions in the tumor treated with S. typhimurium A1-R. Scale bar: 10 mm, 2.5 mm at high magnification. BF: Bright field, GFP: Green fluorescent protein.
Figure 5
Figure 5. Body weight of treated PLPS PDOX mouse models
Bar graphs show the relative body weight of mice treated with each agent. Relative body weight as the body weight at any given time divided by the inhibited body weight. Error bars: ± SD. N.S.: not significant.
Figure 6
Figure 6. Tumor histology
(A) Control tumor (B) Untreated PLPS PDOX. (C) DOX group. (D) S. typhimurium A1-R group. Scale bars: 100μm.
See this image and copyright information in PMC

References

    1. Manji GA, Schwartz GK. Managing Liposarcomas: Cutting Through the Fat. J Oncol Pract. 2016;12:221–227. - PubMed
    1. Guan Z, Yu X, Wang H, Zhang J, Li G, Cao J, Teng L. Advances in the targeted therapy of liposarcoma. Onco Targets Ther. 2015;8:125–136. - PMC - PubMed
    1. Fu X, Le P, Hoffman RM. A metastatic-orthotopic transplant nude mouse model of human patient breast cancer. Anticancer Res. 1993;13:901–904. - PubMed
    1. Fu X, Hoffman RM. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res. 1993;13:283–286. - PubMed
    1. Wang X, Fu X, Hoffman RM. A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice. Int J Cancer. 1992;51:992–995. - PubMed

Publication types

MeSH terms

Substances